Results for “Tests” 696 found
In 2013 I wrote, Our DNA, Our Selves, arguing against the FDA’s crackdown on genetic readouts from firms like 23andMe. The FDA, however, proved succesful in its crackdown and that is why rapid at-home antigen tests are not available today and why tens of thousands of people are dying from COVID unnecessarily. Regulations have unintended consequences.
Consider, I swab the inside of my cheek and send the sample to a firm. The idea that the FDA can rule on what the firm can and cannot tell me about my own genes is absurd–it’s no different than the FDA trying to regulate what my doctor can tell me after a physical examination or what my optometrist can tell me after an eye examination (Please read the first line. “G T A C C A…”).
The idea that the FDA can regulate and control what individuals may learn about their own bodies is deeply offensive and, in my view, plainly unconstitutional.
Let me be clear, I am not offended by all regulation of genetic tests. Indeed, genetic tests are already regulated. To be precise, the labs that perform genetic tests are regulated by the Clinical Laboratory Improvement Amendments (CLIA) as overseen by the CMS (here is an excellent primer). The CLIA requires all labs, including the labs used by 23andMe, to be inspected for quality control, record keeping and the qualifications of their personnel. The goal is to ensure that the tests are accurate, reliable, timely, confidential and not risky to patients. I am not offended when the goal of regulation is to help consumers buy the product that they have contracted to buy.
What the FDA wants to do is categorically different. The FDA wants to regulate genetic tests as a high-risk medical device that cannot be sold until and unless the FDA permits it be sold.
Moreover, the FDA wants to judge not the analytic validity of the tests, whether the tests accurately read the genetic code as the firms promise (already regulated under the CLIA) but the clinical validity, whether particular identified alleles are causal for conditions or disease. The latter requirement is the death-knell for the products because of the expense and time it takes to prove specific genes are causal for diseases. Moreover, it means that firms like 23andMe will not be able to tell consumers about their own DNA but instead will only be allowed to offer a peek at the sections of code that the FDA has deemed it ok for consumers to see.
Ten years later we now need rapid antigen tests but the issue, as Michael Mina points out in an excellent interview with Malcolm Gladwell, is that we have medicalized all tests and readouts. Instead of thinking about the individual as having a right to know about their own body, we treated every test or readout as if the only user were a physician. Thus, instead of thinking about the value of these tests for individuals and for public health, the FDA failed to approve rapid antigen tests because it regarded them as inferior to PCR tests, for a physician diagnosing disease.
Here’s Mina (roughly transcribed and lightly edited)
The only pathway that we have to evaluate tests like this are medical diagnostic pathways, pathways designed specifically to ensure that a physician like a detective is getting all the information they need to diagnose a sick person… We have so devalued and defunded public health…that we don’t have a regulatory pathway to approve a test whose primary objective is stopping an epidemic versus diagnosing a sick person. And that has held everything up. All the companies that could be producing these rapid tests in the millions and millions, they have been sitting on these tests trying to hone them so they can pass FDA standards as a medical diagnostic.
It’s not just slowing down their approval it’s actually bottle necking the companies into creating tests that are not going to be as scalable as they are having to use more expensive reagents and packing the tests with instruments so they can pass FDA review when in reality they are just these little pieces of papers. If we can do the cheap version they can be made very fast but the just won’t get through the FDA.
Gladwell: I find your explanation unconvincing. How dumb is the FDA?…If you make the exact argument you made to me…the FDA is not going to see your logic?
It’s not that they are not smart it’s that this is a regulatory body, they just don’t have a pathway. You can’t apply for approval for a public health test tool…In our country the medical establishment is extremely strong, you can’t go to get a cholesterol test without getting a prescription from your doctor. Why can’t we know that? It’s all through this very heavy medical lens and changing that, getting that big ship to turn is turning out to be a very, very difficult task but leading to potentially tens or hundreds or thousands of deaths that don’t need to be happening.
MPR News: The meeting was slated as a Minneapolis City Council study session on police reform.
But for much of the two-hour meeting, council members told police Chief Medaria Arradondo that their constituents are seeing and hearing street racing which sometimes results in crashes, brazen daylight carjackings, robberies, assaults and shootings. And they asked Arradondo what the department is doing about it.
…Just months after leading an effort that would have defunded the police department, City Council members at Tuesday’s work session pushed chief Medaria Arradondo to tell them how the department is responding to the violence…More people have been killed in the city in the first nine months of 2020 than were slain in all of last year. Property crimes, like burglaries and auto thefts, are also up. Incidents of arson have increased 55 percent over the total at this point in 2019.
Bear in mind this is coming after just a few months of reduced policing, due in part to extra demands and difficulty and probably in part due to police pulling back either out of fear or reluctance (blue flu) as also happened in Baltimore after the Freddie Gray killing and consequent protests and riots.
A few true believers still remain:
Cunningham also criticized some of his colleagues for seeming to waver on the promises they made earlier this year to transform the city’s public safety system.
“What I am sort of flabbergasted by right now is colleagues, who a very short time ago were calling for abolition, are now suggesting we should be putting more resources and funding into MPD,” Cunningham said.
I’m a supporter of unbundling the police and improving policing but the idea that we can defund the police and crime will just melt away is a fantasy. As with bail reform the defunders risk a backlash. Let’s start by decriminalizing more victimless crimes, as we have done in many states with marijuana laws. Let’s work on creating bureaus of road safety. But one of the reasons we do these things is so that we can increase the number of police on the street. The United States is underpoliced and the consequences of underpolicing, as well as overpolicing, fall on minority communities. As I have argued before, we need better policing so that we can all be comfortable with more policing. Getting there, however, will take time.
It’s taken far too long and it’s still not FDA approved for at-home use or for asymptomatic individuals but the new $5,15-minute, easy to use, Abbott test and the Trump administration’s promise to purchase 150 million of them is a big deal. Abbott has been building capacity for months according to their lead scientist interviewed in the Atlantic by Alex Madrigal and in a few weeks will be producing 50 million tests a month:
Madrigal: Fifty million tests a month is a huge number. That’s more than twice the number of tests the U.S. completes in a month. How did you ramp up production so massively?
Hackett: This was the challenge of this program. We needed some sort of reliable testing that could be affordable and that doesn’t require instrumentation. You need scale. The more frequently you could test people, frankly, even tests with lower sensitivity would be very effective at identifying people quickly and slowing the spread. As we were developing the test, there were people working in parallel looking at supply chain and logistics. Abbott took a lot of risk—hundreds of millions of dollars were spent building two new manufacturing facilities focused solely on those tests. We hoped we could come to a solution that would be where we needed it from an overall accuracy perspective, but if you weren’t building capability simultaneously, there was no way it could be the answer.
The US has performed about 80 million tests since the pandemic began, so an additional 50 million tests a month is a big increase in capacity. As noted, the test is not approved for at-home use but it’s a CLIA-waived test which means that a doctor’s office, a CVS or Walmart clinic, even a school nurse could qualify for a waiver and perform the tests. The test is not approved for asymptomatic individuals but I suspect that won’t mean much in practice, it can be prescribed off-label although the fact that a prescription is required is limiting. I hope the necessity for a prescription will be lifted as we get more experience with these tests. False positives (~1.5%) are low and by taking the strain off the PCR system we can improve triage and afford to do more double checks. False positives will be more of an issue as we wipe out the virus but that will take time.
I hope these tests will open up air travel within a month or two. I also hope to see more of these types of tests approved. Derek Lowe has more technical details.
It won’t be all smooth sailing, Abbott may not be able to produce as much or as quickly as they say they can and quality in the field may fall. The government may distribute the tests poorly. The virus could pickup in the fall, as in 1918. I expect more problems and challenges but we now have a chance to get ahead of the virus which is very welcome news.
Addendum: This type of public-private partnership with private firms building capacity in advance of approval for tests and vaccines on the foundation of government push and pull funding is exactly the structure that the Accelerating Health Technologies team has been recommending both to the US government and to governments around the world.
Most theories and hypotheses in psychology are verbal in nature, yet their evaluation overwhelmingly relies on inferential statistical procedures. The validity of the move from qualitative to quantitative analysis depends on the verbal and statistical expressions of a hypothesis being closely aligned—that is,that the two must refer to roughly the same set of hypothetical observations. Here I argue that most inferential statistical tests in psychology fail to meet this basic condition. I demonstrate how foundational assumptions of the “random effects” model used pervasively in psychology impose far stronger constraints on the generalizability of results than most researchers appreciate. Ignoring these constraints dramatically inflates false positive rates and routinely leads researchers to draw sweeping verbal generalizations that lack any meaningful connection to the statistical quantities they are putatively based on. I argue that failure to consider generalizability from a statistical perspective lies at the root of many of psychology’s ongoing problems (e.g.,the replication crisis), and conclude with a discussion of several potential avenues for improvement.
That is from a recent paper by Tal Yarkoni.
If you think the FDA has been slow at approving new coronavirus tests just look at their process for approving sunscreen products.
According to EWG, the Environmental Working Group, the FDA has been too slow to test old ingredients for safety and too slow to allow new ingredients on the market thus leaving us with sunscreen products which are neither as safe nor as effective as they should be. In particular, Europe has better sunscreen protection than the United States. Here’s EWG:
Americans have fewer choices and notably poorer protection than Europeans do from ultraviolet A rays in their sunscreen options. Although most U.S. sunscreens prevent sunburn effectively when used correctly, they aren’t as good as European sunscreens at preventing the more subtle skin damage produced by lower-energy UVA radiation. UVA rays have less energy and don’t burn the skin, but they can cause the skin to age, suppress the immune system and contribute to the development of melanoma.
…Between 2003 and 2010, sunscreen makers applied for FDA permission to use eight sun-filtering chemicals developed by European companies. Four of these – Tinosorb S, Tinosorb M, Mexoryl SX and Mexoryl XL – appear to be more effective than avobenzone, the most common UVA filter permitted by the FDA. The FDA’s failure to respond to these applications prompted Congress to pass the Sunscreen Innovation Act of 2014 (FDA 2014). This act requires the FDA to review new applications for sunscreen active ingredients within 300 days, but it doesn’t relax the standards companies must meet to prove new ingredients are both safe and effective.
In 2015, the FDA responded that the companies involved had not submitted enough information to prove their chemicals were, in fact, safe and effective for use (FDA 2015). The agency asked for more data, including complete study results, measurements of ingredient levels in people’s blood, and long-term studies on systemic toxicity and potential endocrine system disruption. The FDA has also proposed that all sunscreen ingredients, including those already in use, need to have adequate safety testing data.
Some information the FDA wants, such as complete copies of studies, might be easy for sunscreen makers to produce. But in other cases, the companies could take years to satisfy FDA requests. In the meantime, Americans are being shortchanged.
I first wrote about this issue in 2013 and seven years later, despite Congress passing a law in 2014, the FDA still has not acted.
My rule is very simple. I don’t think the FDA is better than the EMA so if any drug or device is approved in Europe it ought to be available for purchase in the United States with a label saying “Approved by the EMA. Not approved by the FDA.” (By the way, we do have reciprocity type agreements with Canada and New Zealand for food so this would not be unprecedented.)
Hat tip: John Thacker.
Addendum: You should actually get more sun to avoid vitamin D deficiency which is bad for a variety of reasons including, in my estimation, greater susceptibility to COVID.
Supply chains were hit hard early in the pandemic. Disinfectant couldn’t be produced because of a lack of bottles, tests couldn’t be processed because nasal swabs or PPE wasn’t available, the decline of passenger air traffic hit commercial delivery and so forth. I worry about forthcoming stresses on the vaccine supply chain. Billions of doses of vaccine will be demanded in the next year and a lot will depend on complicated supply lines including cold storage, air traffic, styrofoam, vials, bags, needles and many other inputs. Companies and the awesome team at CEPI (give them all a Nobel prize) are planning for vials and needles and other inputs but there are many non-obvious inputs higher up in the supply chain that also need shoring up.
Writing in Bloomberg, Scott Duke Kominers and I look at some of the odder inputs to vaccines like horseshoe crab blood, shark livers and the vaccinia capping enyzme, VCE. We are actually not too worried about horseshoe crab blood and shark livers as these are used in other industries. Shark livers, for example, are used to produce a lot of cosmetics so we should be able to divert supply as needed. VCE, however, is rarer.
DNA and mRNA vaccine technologies have shown promising results, and two of the leading vaccine contenders, from Pfizer Inc. and Moderna Inc., use mRNA technology. But mRNA has never been used to produce a commercial vaccine for humans, let alone at scale. And scaling these technologies may not be easy. In particular, mRNA degrades rapidly. To prevent this, it must be “capped” by a very rare substance called vaccinia capping enzyme.
Just over 10 pounds of this VCE is enough to produce a hundred million doses of an mRNA vaccine — but the current manufacturing processes for VCE require so much bioreactor capacity that making 10 pounds would cost about $1.4 billion. More important, global bioreactor capacity cannot support production at that level while also producing other vaccines and cancer-fighting drugs.
If we work hard now, we may be able to find more efficient means of producing VCE. Expanding bioreactor production and repurposing bioreactors from existing large-scale industrial applications will also help to lessen the pressure on the supply chains for multiple types of vaccines.
In addition to supply chains per se we also face the problem that companies are not raising prices enough. Ironically, this means that we need more public investment.
Of course, we might think that private companies would have incentives to coordinate supply chains themselves — and to some extent, they are doing so. But many have pledged to keep their vaccine prices close to costs, both out of altruism and because they may fear public backlash (or legal action) if they’re perceived as “price gouging” in the middle of a pandemic. And if companies don’t stand to profit much from Covid-19 vaccines, then they don’t have much incentive to invest in increasing capacity. In short: If prices can’t rise, then the only way to encourage companies to invest more in production is to reduce their costs — and that means we need public investment.
More generally, it’s not too late to be building more vaccine capacity and to repurpose bioreactor capacity from non-GMP sources, perhaps including veterinary and food sources. There are lots of vaccines in development. The science is promising. We need to take action now so that we can deliver on that promise.
Read the whole thing.
4. Thread on the basics of herd immunity claims. And the NYT covers herd immunity. A very good piece in fact. Semi-herd immunity says I, or “imperfect immunity” to use the terminology of the article. And you will note the extreme epistemological conservatism emanating from the mainstream experts interviewed. Appropriate in some ways, not in others.
7. WSJ review of new Bruno Macaes book on America. The predictions of the book are holding up very well so far!
The FDA has just approved a new and important Covid-19 test:
“Wide-spread testing is critical for our control efforts. We simplified the test so that it only costs a couple of dollars for reagents, and we expect that labs will only charge about $10 per sample. If cheap alternatives like SalivaDirect can be implemented across the country, we may finally get a handle on this pandemic, even before a vaccine,” said Grubaugh.
One of the team’s goals was to eliminate the expensive saliva collection tubes that other companies use to preserve the virus for detection. In a separate study led by Wyllie and the team at the Yale School of Public Health, and recently published on medRxiv, they found that SARS-CoV-2 is stable in saliva for prolonged periods at warm temperatures, and that preservatives or specialized tubes are not necessary for collection of saliva.
Of course this part warmed my heart (doubly):
The related research was funded by the NBA, National Basketball Players Association, and a Fast Grant from the Emergent Ventures at the Mercatus Center, George Mason University.
The NBA had the wisdom to use its unique “bubble” to run multiple tests on players at once, to see how reliable the less-known tests would be. This WSJ article — “Experts say it could be key to increasing the nation’s testing capacity” — has the entire NBA back story. At an estimated $10 a pop, this could especially be a game-changer for poorer nations. Furthermore, it has the potential to make pooled testing much easier as well.
Here is an excerpt from the research pre-print:
The critical component of our approach is to use saliva instead of respiratory swabs, which enables non-invasive frequent sampling and reduces the need for trained healthcare professionals during collection. Furthermore, we simplified our diagnostic test by (1) not requiring nucleic acid preservatives at sample collection, (2) replacing nucleic acid extraction with a simple proteinase K and heat treatment step, and (3) testing specimens with a dualplex quantitative reverse transcription PCR (RT-qPCR) assay. We validated SalivaDirect with reagents and instruments from multiple vendors to minimize the risk for supply chain issues. Regardless of our tested combination of reagents and instruments from different vendors, we found that SalivaDirect is highly sensitive with a limit of detection of 6-12 SARS-CoV-2 copies/μL.
No need to worry and fuss about RNA extraction now. Here is the best simple explanation of the whole thing.
The researchers are not seeking to commercialize their advance, rather they are making it available for the general benefit of mankind. Here is Nathan Grubaugh on Twitter. Here is Anne Wyllie, also a Kiwi and a Kevin Garnett fan. A further implication of course is that the NBA bubble is not “just sports,” but also has boosted innovation by enabling data collection.
All good news of course, and Fast at that. And this:
“This could be one the first major game changers in fighting the pandemic,” tweeted Andy Slavitt, a former acting administrator of the Centers for Medicare and Medicaid Services in the Obama administration, who expects testing capacity to be expanded significantly. “Rarely am I this enthusiastic… They are turning testing from a bespoke suit to a low-cost commodity.”
And here is coverage from Zach Lowe. I am very pleased with the course of Fast Grants more generally, and you will be hearing more about it in the future.
But people aren’t getting their tests back quickly enough.
Well, that’s just stupidity. The majority of all US tests are completely garbage, wasted. If you don’t care how late the date is and you reimburse at the same level, of course they’re going to take every customer. Because they are making ridiculous money, and it’s mostly rich people that are getting access to that. You have to have the reimbursement system pay a little bit extra for 24 hours, pay the normal fee for 48 hours, and pay nothing [if it isn’t done by then]. And they will fix it overnight.
Gates is correct. If companies were paid for speed they would increase capacity and move immediately to a stack processing (LIFO) model, as I described yesterday.
The whole interview is worth reading. Gates is restrained but you can tell he is angry. Bill has had it with the FDA, Trump, Mark Zukerberg, stupid anti-vaxxers like Robert Kennedy (who he was forced to listen to to get access to Trump), Congress and much more. I don’t blame him one bit. I am angry too.
A COVID test that doesn’t come back in a few days is close to useless and PCR tests are taking a long time to process:
NYTimes: Most people who are tested for the virus do not receive results within the 24 to 48 hours recommended by public health experts to effectively stall the virus’s spread and quickly conduct contact tracing, according to a new national survey by researchers from Harvard University, Northeastern University, Northwestern University and Rutgers University….People who had been tested for the virus in July reported an average wait time of about four days. That is about the same wait time for those who reported taking a test in April. Over all, about 10 percent of people reported waiting 10 days or more.
…“A test result that comes back in seven or eight days is worthless for everybody — it shouldn’t even be counted,” said Dr. Amesh Adalja, a senior scholar at the Johns Hopkins University Center for Health Security and a physician in Pittsburgh. “It’s not a test in any kind of effective manner because it’s not actionable.”
One seemingly severe but potential solution is to change how tests are processed. Right now it’s mostly first come, first-served but this means we can easily have a situation where everyone eventually gets a test result but all the results are useless because they take a week or more to process. I propose instead that any test that can’t be reported back in 3-4 days be thrown out immediately. Labs should focus only on processing tests that can be reported back quickly.
One way of thinking about this is to use a stack or last-in first-out (LIFO) model for testing. In a stack model the newest test request is pushed onto the top of the stack and the next test to be processed is popped off the top of the stack. One disadvantage of this model is that some test requests will never be processed (they should be removed from the bottom of the stack and returned as null results). Some people will be angry.
But the stack model of testing has a huge advantage over first-come, first-served. Namely, just as many tests will be completed as under the current model but the tests results will all come back faster and be much more useful. What would you rather have, guaranteed stale test results or fresh results with some possibility of a null return? Since a stale result is not much better than a null it seems obvious that the stack system is superior. Most importantly, faster, more useful tests will help to end the crisis by reducing the number of infections.
Addendum: See also my posts Pooled Testing is Super-Beneficial and Frequent, Fast, and Cheap is Better than Sensitive on other methods to improve testing.
“We must accept the new reality: The virus is widespread on Oahu,” said Anderson, noting that it’s becoming increasingly difficult for contact tracers to pinpoint the source of infection as the virus grows more and more prevalent.
Hawaii now has seen 2,448 positive cases of coronavirus since state health officials started reporting testing results in March. More than 500 of those cases were reported in the last seven days, and most of them are on Oahu.
Historically, about 1% to 2% of tests conducted in Hawaii have come back with positive COVID-19 results. But in recent days that percentage has crept up close to 5%.
“Any time it gets over 5%, there’s reason for concern,” Anderson said. “Some of the states where they’re having large outbreaks have high rates of over 10%. And, obviously, we don’t want to be there.”
The growing prevalence of COVID-19 in Hawaii could jeopardize the state’s ability to reopen public schools, bring college students back to campus and invite visitors to return to Hawaii, said Hawaii Gov. David Ige.
Here is the full story. Of course it is much better to have cases now — when superior treatments are available — than back in March or April. Still, the containment strategies that are supposed to work for the most part…do not in fact work.
As I said in my post Frequent, Fast, and Cheap is Better than Sensitive we shouldn’t be comparing virus tests head-to-head, as if all tests serve the same purpose. Instead, we should recognize that tests have comparative advantages and a cheap, fast, frequent testing regime can be better in some respects than a slow, infrequent but more sensitive testing regime. Both regimes can be useful when used appropriately and especially when they are used in combination.
Eric Topol has a good graphic.
As Topol also notes:
In order to get this done, we need a reboot at @US_FDA, which currently requires rapid tests to perform like PCR tests. That’s wrong. This is a new diagnostic category for the *infectious* endpoint, requiring new standards and prospective validation.
The FDA has sort-of indicated that they might be open to this.
Much, much too slow, of course. Matching a virus that grows exponentially against a risk-averse, overly-cautious FDA has been a recipe for disaster.
You may have read that a number of early games in the season have been cancelled due to many of the players testing positive for Covid-19. There is talk of the season being unsustainable, but it seems a simple remedy has not yet been tried — dock a player 30 percent of his salary if he tests positive. That should limit the degree of nightclubbing and carousing, keeping in mind that the already-infected are probably some of the worst offenders and they have been “taken care of.” Furthermore, the players would have a strong incentive to monitor each other, not wanting to be on the receiving end of an infection from a teammate.
While that arrangement presumably runs counter to the collective bargaining agreement, that agreement can and should be revised if season cancellation is the true alternative.
If need be, the fines can be redistributed to the players who never test positive, thus keeping total compensation constant.
Incentives don’t always work, but if you haven’t even tried them something is amiss. Do I hear “35 percent”? “Forty”? “Thirty-seven percent and three lashes”?
A number of firms have developed cheap, paper-strip tests for coronavirus that report results at-home in about 15 minutes but they have yet to be approved for use by the FDA because the FDA appears to be demanding that all tests reach accuracy levels similar to the PCR test. This is another deadly FDA mistake.
NPR: Highly accurate at-home tests are probably many months away. But Mina argues they could be here sooner if the FDA would not demand that tests for the coronavirus meet really high accuracy standards of 80 percent or better.
A Massachusetts-based startup called E25Bio has developed this sort of rapid test. Founder and Chief Technology Officer Irene Bosch says her firm has field-tested it in hospitals. “What we learned is that the test is able to be very efficient for people who have a lot of virus,” she says.
The PCR tests can discover virus at significantly lower concentration levels than the cheap tests but that extra sensitivity doesn’t matter much in practice. Why not? First, at the lowest levels that the PCR test can detect, the person tested probably isn’t infectious. The cheap test is better at telling whether you are infectious than whether you are infected but the former is what we need to know to open schools and workplaces. Second, the virus grows so quickly that the time period in which the PCR tests outperforms the cheap test is as little as a day or two. Third, the PCR tests are taking days or even a week or more to report which means the results are significantly outdated and less actionable by the time they are reported.
The fundamental issue is this: if a test is cheap and fast we shouldn’t compare it head to head against the PCR test. Instead, we should compare test regimes. A strip test could cost $5 which means you can do one per day for the same price as a PCR test (say $35). Thus, the right comparison is seven cheap tests with one PCR test. So considered a stylized example. If a person gets infected on Sunday and is tested on Sunday then both tests will likely show negative. With the PCR test the infected person then goes to work, infecting other people throughout the week before being the person is tested again next Sunday. With the cheap test the person gets tested again on Monday and again comes up negative and they go to work but probably aren’t infectious. They are then tested again on Tuesday and this time there is enough virus in the person’s system to show positive so on Tuesday the infected person stops going to work and doesn’t infect anyone else. Score one for cheap tests. Now consider what happens if the person gets tested on another day, say Tuesday? In this case, both tests will show positive but the person doesn’t get the results of the PCR test until next Tuesday and so again goes to work and infects other people throughout the week. With the cheap test the infected person learns they are infected and again stops going to work and infecting other people. Score two for cheap tests.
Indeed, when you compare testing regimes it’s hard to come up with a scenario in which infrequent, slow, and expensive but very sensitive is better than frequent, fast, and cheap but less sensitive.
More details in this paper.
Violence in New York is up….In the last 28 days (through July 12), compared to last year, shootings have more than tripled (318 vs. 97). Last week was even worse. If the last 28 days become the new normal, 2021 will have more than 4,100 shootings, a level not seen in well over 20 years.
Undoubtedly bail reform, protests, looting, COVID-19, and the release of prisoners because of COVID all play a role, though how much is debate. What’s less known is how the NYPD has been methodically declawed by design.
Years of political advocacy have resulted in the intentional erosion of legal police authority. There is less prosecution. Most miscreant activities have been decriminalized. The city survived and even benefited from many reforms, but now the camel’s back is breaking.
…For many, this is a feature, not a flaw. A new breed of progressive prosecutors has battled to see who can prosecute the least. As a result, arrests in 2019 decreased 35% from 2016. Reducing incarceration is desirable, and New York has been doing so literally for decades without jeopardizing public safety.
More recently, since November, because of bail reform and COVID releases, the number of jailed inmates dropped another 40%. People are coming out of jail, and few are going in. Many applaud this because incarceration disproportionately affects Black and Brown people.
But so does non-enforcement and the rise in violence. In 2018 (the latest year with published data), 95.7% of shooting victims in New York City are Black or Hispanic. Just 4.3% of victims are white or Asian. When violence goes up, more Black and Hispanic people are shot.